# Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

> **NCT03627728** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 67 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Regorafenib
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03627728
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2022-06-21
- **Final completion:** 2024-10-31
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627728, "Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03627728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*